Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1975 results
November 2026
-
Press release
Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more… -
Press release
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients… -
Press release
Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low… -
Story Access to Healthcare
Novartis ranks No. 1 in 2026 Access to Medicine Index
-
Press release
Novartis ranks first place in 2026 Access to Medicine Index
Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicinesFirst company to achieve No. 1 rank across all Technical Areas since Index began in 2008,… -
Story Discovery
A breakthrough for patients: 25 years of innovation in CML
Over the past twenty-five years, Novartis has helped to pioneer a paradigm shift in our understanding of chronic myeloid leukemia (CML), reshaping how scientists and clinicians approach this rare blood cancer and helping to turn a once-deadly disease into a manageable chronic condition for most patients.
October 2026
-
Story People and Culture
Sometimes the best career plans are the ones you never made
From apprentice to team leader: Nicole Wegscheidler's career shows how curiosity, resilience and growth can unlock unexpected opportunities.
-
Ad hoc release
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Ad hoc announcement pursuant to Art. 53 LRThird quarterQ3 net sales grew +4% (cc¹, +4% USD), with core operating income¹ +10% (cc, +11% USD)Sales growth driven by priority brands including Kisqali (+… -
Ad hoc release
Novartis verzeichnete im dritten Quartal Steigerungen der Umsätze und der Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr erhöht
Ad-hoc-Mitteilung gemäss Art. 53 KRDrittes QuartalDer Nettoumsatz stieg im dritten Quartal um +4% (kWk¹, +4% USD), das operative Kernergebnis¹ verbesserte sich um +10% (kWk, +11% USD)Das… -
Press release
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI… -
Press release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off… -
Press release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval…